Technology | March 22, 2007

ACC: ev3 Stent Cleared for Patients at Risk of Adverse Events from CAD Surgery

When used in conjunction with the ev3 embolic protection device, ev3’s PROTÉGÉ RX Carotid Stent has been FDA cleared for the treatment of carotid artery disease in patients who are at high-risk for adverse events from carotid artery surgery. The cleatance was supported by the CREATE (Carotid Revascularization with ev3 Inc. Arterial Technology Evolution) Trial demonstrating the safety and effectiveness of the PROTÉGÉ Stent and the SPIDER Embolic Protection Device when used together to treat carotid artery disease patients at risk for stroke and also at high-risk for adverse events from surgery.

The PROTÉGÉ RX is available in both straight and tapered stent configurations providing a variety of device options to address a broad range of patient anatomy present in carotid artery disease. The “rapid exchange” platform allows for a single physician to operate the device as compared to “over the wire” designs that require multiple operators.

Related Content

InspireMD, CGuard embolic protection system, EPS, clinical data, internal carotid artery stenosis, ICA
News | Stents Carotid | November 18, 2016
November 18, 2016 — InspireMD Inc.
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid | October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
carotid artery stenting, outcomes, JACC, Beau Hawkins, Robert Yeh, CARE Registry
Feature | Stents Carotid | July 13, 2015
Hospitals performing carotid artery stenting vary considerably in rates of in-hospital stroke or death, according to a...
News | Stents Carotid | June 17, 2015
Karam Moon, M.D., winner of the DePuy Synthes Cerebrovascular Section Resident/Fellow Award, presented his research,...
Overlay Init